Skip to main content
SpringerLink
Log in

Cardiovascular emergencies

  • Chapter
Glucagon in Acute Medicine

Abstract

Receptors for glucagon are found throughout the cardiovascular system. Stimulation of these receptors produces a variety of metabolic and mechanical events in target tissues. Little available data suggests an endogenous role for glucagon in the regulation of the cardiovascular system. However, exogenous administration of supraphysiologic quantities of glucagon can alter cardiovascular performance. In this chapter, we review the effects of pharmacologic administration of glucagon on the cardiac, vascular, and renal systems. We discuss its role in treating disorders of the cardiovascular system, including shock, cardiac insufficiency, and drug overdose with cardiotoxic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Farah AE. Glucagon and the circulation. Pharmacol Rev. 1983;35:181–217.

    PubMed  CAS  Google Scholar 

  2. Farah A, Tuttle R. Studies on the pharmacology of glucagon. J Pharmacol Exp Ther. 1960;129:49–55.

    PubMed  CAS  Google Scholar 

  3. Boder GB, Johnson IS. Comparative effects of some cardioactive agents on the automaticity of cultured heart cells. J Mol Cell Cardiol. 1972;4:453–63.

    Article  PubMed  CAS  Google Scholar 

  4. Glick G, Parmley WW, Wechsler AS, Sonnenblick EH. Glucagon: its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circ Res. 1968;22:789–99.

    Article  PubMed  CAS  Google Scholar 

  5. Lucchesi BR. Cardiac actions of glucagon. Circ Res. 1968;22:777–87.

    Article  PubMed  CAS  Google Scholar 

  6. Regan TJ, Lehan PH, Hennemann DH, Behar A, Hellems HK. Myocardial, metabolic and contractile response to glucagon and epinephrine. J Lab Clin Med. 1964;63:638–647.

    PubMed  CAS  Google Scholar 

  7. Moura AM, Simpkins H. Cyclic AMP levels in cultured myocardial cells under the influence of chronotropic and inotropic agents. J Mol Cell Cardiol. 1975;7:71–7.

    Article  CAS  Google Scholar 

  8. Marsiglia JC, Moreyra AE, Lardani H, Cingolani HE. Glucagon: its effect upon myocardial oxygen consumption. Eur J Pharmacol. 1970;12:265–70.

    Article  PubMed  CAS  Google Scholar 

  9. Simaan J, Fawaz G. The cardiodynamic and metabolic effects of glucagon. Naunyn Schmiedebergs Arch Pharmacol. 1976;294:277–83.

    Article  PubMed  CAS  Google Scholar 

  10. Kones RJ, Phillips JH. Glucagon: present status in cardiovascular disease. Clin Pharmacol Ther. 1971;12:427–44.

    PubMed  CAS  Google Scholar 

  11. Smitherman TC, Osborn RC Jr, Atkins JM. Cardiac dose response relationship for intravenously infused glucagon in normal intact dogs and men. Am Heart J. 1978;96: 363–71.

    Article  PubMed  CAS  Google Scholar 

  12. Abel FL. Action of glucagon on canine left ventricular performance and coronary hemodynamics. Circ Shock. 1983;11:45–58.

    PubMed  CAS  Google Scholar 

  13. MacLeod KM, Rodgers RL, McNeill JH. Characterization of glucagon-induced changes in rate, contractility and cyclic AMP levels in isolated cardiac preparations of the rat and guinea pig. J Pharmacol Exp Ther. 1981;217:798–804.

    PubMed  CAS  Google Scholar 

  14. Zaloga GP, Malcolm DS, Holaday JW, Chernow B. Glucagon. In: Chernow B, editor. The pharmacologic approach to the critically ill patient. Second edition. Baltimore: Williams and Wilkins; 1988;659–70.

    Google Scholar 

  15. Chernow B, Reed L, Geelhoed GW, Anderson M, Teich S, Meyerhoff J, Beardsley D, Lake CR, Holaday JW. Glucagon: endocrine effects and calcium involvement in cardiovascular actions in dogs. Circ Shock. 1986;19:393–407.

    PubMed  CAS  Google Scholar 

  16. Ross EM, Gilman AG. Biochemical properties of hormone-sensitive adenylate cyclase. Annu Rev Biochem. 1980;49:533–64.

    Article  PubMed  CAS  Google Scholar 

  17. Xenophontos XP, Watson PA, Chua BH, Haneda T, Morgan HE. Increased cyclic AMP content accelerates protein synthesis in rat heart. Circ Res. 1989;65:647–56.

    Article  PubMed  CAS  Google Scholar 

  18. Mery PF, Brechler V, Pavoine C, Pecker F, Fischmeister R. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature. 1990;345:148–61.

    Article  Google Scholar 

  19. Pullman TN, Lavender AR, Aho I. Direct effects of glucagon on renal hemodynamics and excretion of inorganic ions. Metabolism. 1967;16:358–73.

    Article  PubMed  CAS  Google Scholar 

  20. Barritt GJ, Speil PF. Effects of glucagon on 45Ca outflow exchange in the isolated perfused rat heart. Biochem Pharmacol. 1981;30:1407–14.

    Article  PubMed  CAS  Google Scholar 

  21. Nayler WG, McInnes I, Chipperfield D, Carson V, Daile P. The effect of glucagon on calcium exchangeability, coronary blood flow, myocardial function and high energy phosphate stores. J Pharmacol Exp Ther. 1970;171:265–75.

    PubMed  CAS  Google Scholar 

  22. Pavoine C, Brechler V, Kervran A, Blache P, Le-Nguyen D, Lament S, Bataille D, Pecker F. Miniglucagon [glucagon-(19–29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991;260:C993–9.

    PubMed  CAS  Google Scholar 

  23. Wildenthal K, Allen DO, Karlsson J, Wakeland JR, Clark CM Jr. Responsiveness to glucagon in fetal hearts. Species variability and apparent disparities between changes in beating, adenylate cyclase activation, and cyclic AMP concentration. J Clin Invest. 1976;57:551–8.

    Article  PubMed  CAS  Google Scholar 

  24. Chemow B, Zaloga GP, Malcolm D, Willey SC, Clapper M, Holaday JW. Glucagon’s chronotropic action is calcium dependent. J Pharmacol Exp Ther. 1987;241:833–7.

    Google Scholar 

  25. Prielipp RC, Hill T, Washburn D, Zaloga GP. Circulating calcium modulates adrenaline-induced cyclic adenosine monophosphate production. Cardiovasc Res. 1989;23:838–41.

    Article  PubMed  CAS  Google Scholar 

  26. Talesnik J, Tsoporis J. Enhancement by glutathione of the inotropic actions of catecholamines and glucagon. J Mol Cell Cardiol. 1984;16:573–6.

    Article  PubMed  CAS  Google Scholar 

  27. Drucker MR, Pindyck F, Brown RS, Elwyn DH, Shoemaker WC. The interaction of glucagon and glucose on cardiorespiratory variables in the critically ill patient. Surgery. 1974;75:487–95.

    Google Scholar 

  28. Malcolm D, Zaloga G, Chemow B, Holaday J. Glucagon is an antagonist of morphine bradycardia and antinociception. Life Sci. 1986;39:399–405.

    Article  PubMed  CAS  Google Scholar 

  29. Brogan E, Kozonis MC, Overy DC. Glucagon therapy in heart failure. Lancet. 1969;1: 482–4.

    Article  PubMed  CAS  Google Scholar 

  30. Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med. 1968;279:12–7.

    Article  PubMed  CAS  Google Scholar 

  31. Lvoff R, Wilcken DE. Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients. Circulation. 1972;45:534–42.

    Article  PubMed  CAS  Google Scholar 

  32. Parmley WW, Matloff JM, Sonnenblick EH. Hemodynamic effects of glucagon in patients following prosthetic valve replacement. Circulation. 1969;39,suppl I:163–7.

    Google Scholar 

  33. Eddy JD, O’Brien ET, Singh SP. Glucagon and haemodynamics of acute myocardial infarction. Br Med J. 1969;4:663–5.

    Article  PubMed  CAS  Google Scholar 

  34. Wilcken DE, Lvoff R. Glucagon in resistant heart-failure and cardiogenic shock. Lancet. 1970;1:1315–18.

    Article  Google Scholar 

  35. Siegel JH, Levine MJ, McConn R, DelGuercio LR. The effect of glucagon infusion on cardiovascular function in the critically ill. Surg Gynecol Obstet. 1970;131:505–15.

    PubMed  CAS  Google Scholar 

  36. Armstrong PW, Gold HK, Daggett WM, Austen WG, Sanders CA. Hemodynamic evaluation of glucagon in symptomatic heart disease. Circulation. 1971;44:67–73.

    Article  PubMed  CAS  Google Scholar 

  37. Westlie L, Andersen A, Jervell J, Rassmussen K, Storstein O. Cardiovascular effects of glucagon. Acta Med Scand. 1971;189:179–84.

    Article  PubMed  CAS  Google Scholar 

  38. Goldstein RE, Skelton CL, Levey GS, Glancy DL, Beiser GD, Epstein SE. Effects of chronic heart failure on the capacity of glucagon to enhance contractility and adenyl cyclase activity of human papillary muscles. Circulation. 1971;44:638–48.

    Article  PubMed  CAS  Google Scholar 

  39. Parmley WW, Chuck L, Matloff J. Diminished responsiveness of the failing human myocardium to glucagon. Cardiology. 1970;55:211–7.

    Article  PubMed  CAS  Google Scholar 

  40. Segel LD. Alcoholic cardiomyopathy in rats: inotropic responses to phenylephrine, glucagon, ouabain, and dobutamine. J Mol Cell Cardiol. 1987;19:1061–72.

    Article  PubMed  CAS  Google Scholar 

  41. Jolly SR, Jordan J, Rose G. Stimulation of myocardial function after brief ischemia by glucagon. Drug Dev Res. 1991;22:125–34.

    Article  CAS  Google Scholar 

  42. Niemann JT, Haynes KS, Garner D, Jagels G, Rennie Q. Postcountershock pulseless rhythms: hemodynamic effects of glucagon in a canine model. Crit Care Med. 1987;15:554–8.

    Article  PubMed  CAS  Google Scholar 

  43. Prasad K. Electrophysiologic effects of glucagon on human cardiac muscle. Clin Pharmacol Ther. 1975;18:22–30.

    PubMed  CAS  Google Scholar 

  44. Curry CL, Hinds JE, Hawthorne EW. The effect of glucagon on the ventricular response in atrial fibrillation. A possible hazard. Am J Cardiol. 1972;29:258 (abstract).

    Article  Google Scholar 

  45. Hawthorne EW, Hinds JE. Experimental atrial fibrillation in conscious dogs. Am J Cardiol. 1972;29:269 (abstract).

    Article  Google Scholar 

  46. Parmley WW, Sonnenblick EH. A role for glucagon in cardiac therapy. Am J Med Sci. 1969;258:224–9.

    PubMed  CAS  Google Scholar 

  47. Lucchesi BR, Stutz DR, Winfield RA. Glucagon: its enhancement of atrioventricular nodal pacemaker activity and failure to increase ventricular automaticity in dogs. Circ Res. 1969;25:183–90.

    Article  PubMed  CAS  Google Scholar 

  48. Madan BR. Effect of glucagon on ventricular arrhythmias after coronary artery occlusion and on ventricular automaticity in the dog. Br J Pharmacol. 1971;43:279–86.

    PubMed  CAS  Google Scholar 

  49. Singh J, Bala S, Kaur AH, Garg KN. Effect of glucagon on arrhythmias induced by coronary artery occlusion and ouabain in dogs. Indian J Physiol. 1980;24:329–34.

    CAS  Google Scholar 

  50. Lekven J, Kjekshus JK, Mjos OD. Effects of glucagon and isoproterenol on severity of acute myocardial ischemic injury. Scand J Clin Lab Invest. 1973;32:129–37.

    Article  PubMed  CAS  Google Scholar 

  51. Maroko PR, Kjekshus JK, Sobel BE, Watanable T, Covell JW, Ross J Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43:67–82.

    Article  PubMed  CAS  Google Scholar 

  52. Shell WE, Sobel BE. Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol. 1973;31:474–9.

    Article  PubMed  CAS  Google Scholar 

  53. Whitsitt LS, Lucchesi BR. Effects of beta-receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circ Res. 1968;23:585–95.

    Article  PubMed  CAS  Google Scholar 

  54. Peterson A, Lucceshi B, Kirsh MM. The effect of glucagon in animals on chronic propranolol therapy. Ann Thorac Surg. 1978;25:340–5.

    Article  PubMed  CAS  Google Scholar 

  55. Agura ED, Wexler LF, Witzburg RA. Massive propranolol overdose: successful treatment with high-dose isoproterenol and glucagon. Am J Med. 1986;80:755–7.

    Article  Google Scholar 

  56. Zaloga GP, Delacey W, Holmboe E, Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med. 1986;105:65–6.

    PubMed  CAS  Google Scholar 

  57. Peterson CD, Leeder JS, Sterner S. Glucagon therapy for β-blocker overdose. Drug Intell Clin Pharm. 1984;18:394–8.

    PubMed  CAS  Google Scholar 

  58. Tai YT, Lo CW, Chow WH, Cheng CH. Successful resuscitation and survival following massive overdose of metoprolol. Br J Clin Pract. 1990;44:746–7.

    PubMed  CAS  Google Scholar 

  59. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984;13:1123–31.

    Article  PubMed  CAS  Google Scholar 

  60. Urthaler F, Isobe JH, James TN. Comparative effects of glucagon on automaticity of the sinus node and atrioventricular junction. Am J Physiol. 1974;227:1415–21.

    PubMed  CAS  Google Scholar 

  61. Prasad K, Weckworth P. Glucagon in procainamide-induced cardiac toxicity. Toxicol Appl Pharmacol. 1978;46:517–28.

    Article  PubMed  CAS  Google Scholar 

  62. Prasad K. Use of glucagon in the treatment of quinidine toxicity in the heart. Cardiovasc Res. 1977;11:53–63.

    Article  Google Scholar 

  63. Cohn KE, Agmon J, Gamble OW. The effect of glucagon on arrhythmias to digitalis toxicity. Am J Cardiol. 1970;25:683–9.

    Article  PubMed  CAS  Google Scholar 

  64. Prasad K, DeSousa HH. Glucagon in the treatment of ouabain-induced cardiac arrhythmias in dogs. Cardiovasc Res. 1972;6:333–43.

    Article  PubMed  CAS  Google Scholar 

  65. Gupta MM, Prasad K. Studies of the effects of glucagon on ouabain-induced cardiac disorders using the PISA method. In: Tajuddin M, Das PK, Tariq M, Dhalla NS, editors. Advances in Myocardiology. Vol. 1. Baltimore: University Press; 1980:313–9.

    Google Scholar 

  66. Jolly SR, Kipnis JN, Lucchesi BR. Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol. Pharmacology. 1987;35:249–55.

    Article  PubMed  CAS  Google Scholar 

  67. Sabatier J, Pouyet T, Shelvey G, Cavero I. Antagonistic effects of epinephrine, glucagon and methylatropine but not calcium chloride against atrio-ventricular conduction disturbances produced by high doses of diltiazem, in conscious dogs. Fundam Clin Pharmacol. 1991;5:93–106.

    Article  PubMed  CAS  Google Scholar 

  68. Zaritsky AL, Horowitz M, Chemow B. Glucagon antagonism of calcium channel blockerinduced myocardial dysfunction. Crit Care Med. 1988;16:246–51.

    Article  PubMed  CAS  Google Scholar 

  69. Zaloga GP, Malcolm D, Holaday J, et al. Glucagon reverses the hypotension and bradycardia of verapamil overdose in rats. Crit Care Med. 1985;13:273 (abstract).

    Article  Google Scholar 

  70. Stewart JW, Myerburg RJ, Hoffman BF. The effect of glucagon on quinidine-induced changes in Purkinje fibers. Circulation. 1969;40:196.

    Google Scholar 

  71. Crump BI, Holt DW, Vales JA. Lack of response to intravenous calcium in severe verapamil poisoning. Lancet. 1982;1:939–940.

    Article  Google Scholar 

  72. Kazmers A, Whitehouse WM Jr, Lindenauer SM, Stanley JC. Dissociation of glucagon’s central and peripheral hemodynamic effects: mechanisms of reduction and redistribution of canine hindlimb blood flow. J Surg Res. 1981;30:384–90.

    Article  PubMed  CAS  Google Scholar 

  73. Tibblin S, Kock NG, Schenk WG Jr. Response of mesenteric blood flow to glucagon. Influence of pharmacological stimulation and blockade of adrenergic receptors. Arch Surg. 1971;102:65–70.

    Article  PubMed  CAS  Google Scholar 

  74. Kock NG, Tibblin S, Schenk WG Jr. Hemodynamic responses to glucagon: an experimental study of central, visceral and peripheral effects. Ann Surg. 1970;171:373–9.

    Article  PubMed  CAS  Google Scholar 

  75. Madden JJ Jr, Ludewig RM, Wagensteen SL. Effects of glucagon on the splanchnic and the systemic circulation. Am J Surg. 1971;122:85–90.

    Article  PubMed  CAS  Google Scholar 

  76. Okamura T, Miyazaki M, Toda N. Responses of isolated dog blood vessels to glucagon. Eur J Pharmacol. 1986;125:395–401.

    Article  PubMed  CAS  Google Scholar 

  77. D’Almeida MS, Lautt WW. The effect of glucagon on vasoconstriction and vascular escape from nerve and norepinephrine-induced constriction of the hepatic artery of the cat. Can J Physiol Pharmacol. 1989;67:1418–25.

    Article  PubMed  Google Scholar 

  78. Kock NG, Tibblin S, Schenk WG Jr. Modification by glucagon of the splanchnic vascular responses to activation of the sympathicoadrenal system. J Surg Res. 1971;11:12–7.

    Article  PubMed  CAS  Google Scholar 

  79. Richardson PD, Withrington PG. The inhibition by glucagon of the vasoconstrictor actions of noradrenaline, angiotensin and vasopressin on the hepatic arterial vascular bed of the dog. Br J Pharmacol. 1976;57:93–102.

    Article  PubMed  CAS  Google Scholar 

  80. D’Almeida MS, Lautt WW. Glucagon pharmacodynamics and modulation of sympathetic nerve and norepinephrine-induced constrictor responses in the superior mesenteric artery of the cat. J Pharmacol Exp Ther. 1991;259:118–23.

    PubMed  Google Scholar 

  81. Wright CD, Kazmers A, Whitehouse WM Jr, Stanley JC. Comparative hemodynamic effects of selective superior mesenteric arterial and peripheral intravenous glucagon infusions. J Surg Res. 1985;39:230–6.

    Article  PubMed  CAS  Google Scholar 

  82. Cronenwett JL, Ayad M, Kazmers A. Effect of intravenous glucagon on the survival of rats after acute occlusive mesenteric ischemia. J Surg Res. 1985;38:446–52.

    Article  PubMed  CAS  Google Scholar 

  83. Kazmers A, Zwolak R, Appelman HD, Whitehouse WM Jr, Wu SC, Zelenock GB, Cronenwett JL, Lindenauer SM, Stanley JC. Pharmacologic interventions in acute mesenteric ischemia: improved survival with intravenous glucagon, methylprednisolone, and prostacyclin. J Vasc Surg. 1984;1:472–81.

    PubMed  CAS  Google Scholar 

  84. Boorstein JM, Dacey LJ, Cronenwett JL. Pharmacologic treatment of occlusive mesenteric ischemia in rats. J Surg Res. 1988;44:555–60.

    Article  PubMed  CAS  Google Scholar 

  85. Sardella GL, Bech FR, Cronenwett JL. Hemodynamic effects of glucagon after acute mesenteric ischemia in rats. J Surg Res. 1990;49:354–60.

    Article  PubMed  CAS  Google Scholar 

  86. Clark ET, Gewertz BL. Glucagon potentiates intestinal reperfusion injury. J Vasc Surg. 1990;11:270–9.

    PubMed  CAS  Google Scholar 

  87. Bond JH, Levitt MD. Use of microspheres to measure small intestinal villus blood flow in the dog. Am J Physiol. 1979;236:577–83.

    Google Scholar 

  88. Oshima A, Kitajima M, Sakai N, Ando N. Does glucagon improve the viability of ischemic intestine? J Surg Res. 1990;49:524–33.

    Article  PubMed  CAS  Google Scholar 

  89. Bond JH, Levitt MD. Effect of glucagon on gastrointestinal blood flow of dogs in hypovolemic shock. Am J Physiol. 1980;238:G434–9.

    PubMed  CAS  Google Scholar 

  90. Katz AI, Lindheimer MD. Actions of hormones on the kidney. Annu Rev Physiol. 1977;39:97–133.

    Article  PubMed  CAS  Google Scholar 

  91. Danford RO. The effect of glucagon on renal hemodynamics and renal arteriography. Am J Roentgenol Radium Ther Nucl Med. 1970;108:665–73.

    PubMed  CAS  Google Scholar 

  92. Gagnon G, Regoli D, Rioux F. Studies on the mechanism of action of glucagon in strips of rabbit renal artery. Br J Pharmacol. 1980;69:389–96.

    Article  PubMed  CAS  Google Scholar 

  93. Aki Y, Shoji T, Hasui K, Fukui K, Tamaki T, Iwao H, Abe Y. Intrarenal vascular sites of action of adenosine and glucagon. Jpn J Pharmacol. 1990;54:433–40.

    Article  PubMed  CAS  Google Scholar 

  94. Ueda J, Nakanishi H, Miyazaki AM, Abe Y. Effects of glucagon on the renal hemodynamics of dogs. Eur J Pharmacol. 1977;41:209–12.

    Article  PubMed  CAS  Google Scholar 

  95. Kirschenbaum MA, Zawada ET. The role of prostaglandins in glucagon-induced natriuresis. Clin Sci. 1980;58:393–401.

    PubMed  CAS  Google Scholar 

  96. VanderWall DA, Stowe NT, Spangenberg R, Hook JB. Effect of glucagon in hemorrhagic shock. J Surg Oncol. 1970;2:177–87.

    Article  PubMed  CAS  Google Scholar 

  97. Bowman HM, Cowan D, Kovach G Jr, Hook JB. Renal effects of glucagon in rhesus monkeys during hypovolemia. Surg Gynecol Obstet. 1972;134:937–41.

    PubMed  CAS  Google Scholar 

  98. Lindsey A, Santeusanio F, Braaten J, Faloona GR, Unger RH. Pancreatic alpha-cell function in trauma. JAMA. 1974;227:757–61.

    Article  PubMed  CAS  Google Scholar 

  99. Wilmore DW, Lindsey CA, Moyland JA, Faloona GR, Pruitt BA, Unger RH. Hyperglucagonaemia after bums. Lancet. 1974;1:73–5.

    Article  PubMed  CAS  Google Scholar 

  100. McLeod MK, Carlson DE, Gann DS. Secretory response of glucagon to hemorrhage. J Trauma. 1983;23:445–52.

    Article  PubMed  CAS  Google Scholar 

  101. Ishida K, Hinshaw LB. Change of plasma gastrointestinal glucagon concentrations following lethal infusions of E. coli. Circ Shock. 1986;19:301–8.

    PubMed  CAS  Google Scholar 

  102. Manson NH, Hess ML. Role of angiotensin I and glucagon in canine endotoxin shock: effect of converting enzyme inhibitor and prior immunization. Circ Shock. 1984;12:177–89.

    PubMed  CAS  Google Scholar 

  103. Jain KM, Rush BF Jr, Hastings OM, Ghosh A, Slotman G, Albousamra S. Glucagon treatment of hemorrhagic shock: improved survival and metabolic parameters in a murine shock model. Adv Shock Res. 1978;1:149–57.

    PubMed  CAS  Google Scholar 

  104. Bower MG, Okuda S, Jolley WB, Smith LL. Hemodynamic effects of glucagon following hemorrhagic and entotoxic shock in the dog. Arch Surg. 1970;101:411–15.

    Article  PubMed  CAS  Google Scholar 

  105. Guillen J, Pappas G. Improved cardiovascular effects of glucagon in dogs with endotoxin shock. Ann Surg. 1972;175:535–8.

    Article  PubMed  CAS  Google Scholar 

  106. Weingand KW, Fettman MJ, Phillips RW, Hand MS. Metabolic effects of glucagon in endotoxemic minipigs. Circ Shock. 1986;18:289–300.

    PubMed  CAS  Google Scholar 

  107. Markovitz LJ, Hasin Y, Freund HR. The effect of insulin and glucagon on systolic properties of the normal and septic isolated rat heart. Basic Res Cardiol. 1985;80: 377–83.

    Article  PubMed  CAS  Google Scholar 

  108. Andjelkovic I, Zlokovic B. Protective effects of glucagon during the anaphylactic response in guinea-pig isolated heart. Br J Pharmacol. 1982;76:483–9.

    Article  PubMed  CAS  Google Scholar 

  109. Weigelt JA, Gewertz BL, Aurbakken CM, Snyder WH. Pharmacologic alterations in pulmonary artery pressure in the adult respiratory distress syndrome. J Surg Res. 1982;32:243–8.

    Article  PubMed  CAS  Google Scholar 

  110. Scian LF, Westermann CD, Verdesca AS, Hilton JG. Adrenocortical and medullary effects of glucagon. Am J Physiol. 1960;199:867–70.

    PubMed  CAS  Google Scholar 

  111. Lawrence AM. Glucagon provocative test for pheochromocytoma. Ann Intern Med. 1967;66:1091–6.

    PubMed  CAS  Google Scholar 

  112. Schorr RT, Rogers SN. Intraoperative cardiovascular crisis caused by glucagon. Arch Surg. 1987;122:833–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesia and Medicine Head, Section of Critical Care Medical Center Boulevard, Bowman Gray School of Medicine Wake Forest University, Winston-Salem, North Carolina, 27157-1009, USA

    Prof. Gary P. Zaloga

Authors
  1. Prof. Gary P. Zaloga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

J. Picazo MD

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Zaloga, G.P. (1993). Cardiovascular emergencies. In: Picazo, J. (eds) Glucagon in Acute Medicine. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-2220-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-2220-7_2

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4984-9

  • Online ISBN: 978-94-011-2220-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation